Last reviewed · How we verify
NCT04147325
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
trial testing Antiretroviral Therapy in HIV in 105 participants. Completed in 12 December 2022.
12 December 2022
Quick facts
| Lead sponsor | Janssen-Cilag Farmaceutica Ltda. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 105 |
| Start date | 17 December 2019 |
| Primary completion | 12 December 2022 |
| Estimated completion | 12 December 2022 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- Antiretroviral Therapy — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
Sponsor
Janssen-Cilag Farmaceutica Ltda. — full company profile →
Who can join
18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the proportion of newly diagnosed participants with Human Immunodeficiency Virus (HIV)-1 (naive participants) with virologic response at Week 48-defined as HIV-1 Ribonucleic acid (RNA) less than (\<) 50 copies/milliliter (mL) (Food And Drug Administration snapshot) - after the implementation of the Test \& Treat model of care and in a historical cohort.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04147325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Antiretroviral Therapy
Trials testing the same drug.
- NCT05330143 — Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV · Phase 2 · completed
- NCT04297501 — Gut Microbiota Changes of HIV Patients Before and After One Year of ART · completed
- NCT02595866 — Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patie · Phase 1 · completed
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other Janssen-Cilag Farmaceutica Ltda. trials
Trials by the same sponsor.
- NCT04268628 — A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Meta · completed
- NCT03666715 — A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utiliz · completed
- NCT02437019 — Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) · approved for marketing
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04147325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag Farmaceutica Ltda.
- Last refreshed: 11 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04147325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing